Napredna pretraga

Pregled bibliografske jedinice broj: 652485

Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3- year follow up study


Markić, Joško; Polić, Branka; Stričević, Luka; Metličić, Vitomir; Kuzmanić Samija, Radenka; Kovačević, Tanja; Erceg Ivkošić, Ivana; Meštrović, Julije
Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3- year follow up study // Wiener klinische Wochenschrift, 126 (2014), 3/4; 133-137 doi:10.1007/s00508-013-0475-3 (međunarodna recenzija, članak, znanstveni)


Naslov
Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3- year follow up study

Autori
Markić, Joško ; Polić, Branka ; Stričević, Luka ; Metličić, Vitomir ; Kuzmanić Samija, Radenka ; Kovačević, Tanja ; Erceg Ivkošić, Ivana ; Meštrović, Julije

Izvornik
Wiener klinische Wochenschrift (0043-5325) 126 (2014), 3/4; 133-137

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Glycogen Storage Disease Type II; Infantile; Immunomodulation; Rituximab; Cardiomyopathy

Sažetak
Pompe disease is a storage disorder characterized by deficient or absent activity of the enzyme acid alpha-glucosidase. As a result of ineffective metabolism, glycogen accumulates in muscle tissues. Patients with a classic infantile-onset form present by the first few months of life with hypertrophic cardiomyopathy and muscle weakness. If left untreated, these patients rapidly die of cardiorespiratory failure. A cross-reactive immunological material (CRIM)-negative status is predictive of high anti-alglucosidase alfa antibody titers. However, CRIM-positive patients also sometimes develop robust antibody titers. High antibody titers complicate therapeutic management, and those patients have a worse clinical outcome of enzyme replacement therapy (ERT). Four years ago, we successfully used an immune modulation therapy (IMT) protocol in a CRIM- positive infantile-onset patient with Pompe disease in whom ERT had to be discontinued because of severe infusion-associated reactions. She was found to be positive for anti-alglucosidase alfa antibodies. IMT (rituximab, methotrexate and intravenous gammaglobulin) was started, and ERT was safely reintroduced during the IMT induction phase without any complications. Antibodies disappeared, IMT was tapered and discontinued, and cadiomyopathy steadily improved. During more than three years of follow up, she remained ventilator- dependent and no gains in motor skills were noticed. The antibodies are still undetectable and no adverse reactions associated with IMT had occurred. The cardiomyopathy is gradually increasing, but there is still ~50% reduction as compared to the highest value measured. Although the reversal of clinical decline in our CRIM- positive and antibody-positive infant cannot be solely attributed to IMT, this protocol proved itself efficient and safe.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati